Consensus BioNTech SE Börse Stuttgart

Equities

22UA

US09075V1026

Real-time Estimate Tradegate Other stock markets 14:17:37 2024-05-08 EDT			5-day change	1st Jan Change
83.72 ^EUR	-1.09%		+1.74%	-5.76%

05:37pm	HC Wainwright Raises BioNTech SE Price Target to $113 From $107, Maintains Buy Rating	MT
04:15pm	BIONTECH : Deutsche Bank reaffirms its Neutral rating	ZD

Evolution of the average Target Price on BioNTech SE

Price target over the last 5 years

History of analyst recommendation changes

d578b611764e4.zNpyk4Ful0l-haGCiM6Seriv9AFzBA7aBn1C-eSBJIs.hugjp8Aswz0V9My6vqHXN9T5jWMrNlqeXjsUtaj3HeSEuAvk5A2kKgn1mQ~43adc4701c8f130b1750a8c13b2b51ee

Analyst Recommendations on BioNTech SE

HC Wainwright Raises BioNTech SE Price Target to $113 From $107, Maintains Buy Rating	11:37am	MT
BIONTECH : Deutsche Bank reaffirms its Neutral rating	10:15am	ZD
TD Cowen Adjusts BioNTech Price Target to $98 From $95, Maintains Hold Rating	05-07	MT
BMO Capital Adjusts BioNTech Price Target to $122 From $123, Maintains Outperform Rating	05-07	MT
BIONTECH : Goldman Sachs reiterates its Neutral rating	05-07	ZD
BIONTECH : Jefferies gives a Neutral rating	05-06	ZD
BIONTECH : Gets a Neutral rating from Deutsche Bank	04-23	ZD
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating	03-27	MT
BIONTECH : Deutsche Bank remains Neutral	03-22	ZD
TD Cowen Adjusts BioNTech Price Target to $95 From $101, Maintains Market Perform Rating	03-21	MT
BIONTECH : A miss is a miss	03-21
BIONTECH : Deutsche Bank reaffirms its Neutral rating	03-21	ZD
BIONTECH : Goldman Sachs reiterates its Neutral rating	03-21	ZD
BIONTECH : Jefferies sticks Neutral	03-20	ZD
BIONTECH : UBS gives a Neutral rating	03-20	ZD
BMO Capital Initiates Coverage on BioNTech With Outperform Rating, $127 Price Target	02-23	MT
Canaccord Genuity Adjusts Price Target on BioNTech to $171 From $168, Maintains Buy Rating	02-20	MT
HC Wainwright Adjusts BioNTech Price Target to $107 From $133, Maintains Buy Rating	01-23	MT
WHO sees 'incredibly low' COVID, flu vaccination rates as cases surge	01-12	RE
BIONTECH : UBS sticks Neutral	01-09	ZD
Oppenheimer Initiates BioNTech With Perform Rating	01-05	MT
BIONTECH : UBS gives a Neutral rating	12-14	ZD
BIONTECH : Jefferies remains Neutral	12-12	ZD
Morgan Stanley Lifts Price Target on BioNTech to $112 From $111, Keeps Equalweight Rating	12-12	MT
JPMorgan Chase Downgrades BioNTech to Underweight From Neutral, Cuts Price Target to $99 From $106	12-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

84.31 EUR

Average target price

106.6 EUR

Spread / Average Target

+26.48%

High Price Target

158.7 EUR

Spread / Highest target

+88.24%

Low Price Target

82.88 EUR

Spread / Lowest Target

-1.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BioNTech SE

DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
TD Cowen
BMO Capital
JEFFERIES	Akash Tewari
GOLDMAN SACHS	Chris Shibutani
UBS
alphavalue	Martin Schnee
Canaccord Genuity
HC Wainwright
Oppenheimer
Morgan Stanley
JPMorgan Chase
JPMORGAN	Jessica Fye
HSBC
Deutsche Bank Securities
BERENBERG	Zhiqiang Shu
Redburn
Berenberg Bank
BofA Securities
Jefferies & Co.
SVB Securities LLC
Kempen
DEUTSCHE BANK	Emmanuel Papadakis
SVB Leerink
BRYAN GARNIER	Olga Smolentseva
Bryan, Garnier & Co.
Wolfe Research
J.P. Morgan Chase

Ratings for BioNTech SE

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar